Immunoenzymometric assays (lEMAs) for human insulin and intact proinsulin were developed using the amplification system developed by Johannsson et al. (Clin. Chim. Acta 148 (1985) 119 -124) for the detection of the enzyme alkaline phosphatase. The detection limit of the assays was 0.8 pmol/1 for proinsulin and 0.8 pmol/1 for insulin whereas it was 1.8 pmol/1 and 2.3 pmol/1 respectively for the homologous immunoradiometric assays (IRMA). These assays are superior to immunoradiometric assays in terms of sensitivity, shelf-life of the labelled antibody and suitability for automation.
Introduction
We have established new monoclonal antibody based two-site immunoradiometric assays (IRMAs) specific for insulin, proinsulin, 32 -33 split and 65 -66 split proinsulins (1) . These assays have provided new information concerning the changes of insulin and proinsulin in Type II diabetes (2) . However, the sensitivity of the immunoradiometric assay is barely adequate for the accurate determination of intact proinsulin in plasma from fasting normal subjects. In addition, assays based upon the use of 125 I as an antibody label and cellulose solid phase are not ideal for the analysis of large numbers of samples. In order to 1 avoid the frequent iodinations necessitated by the use of 125 I-labelled reagents immunoenzymometric assays (IBMAs) have been developed using an alkaline phosphatase-labelled monoclonal antibody and an amplification system for measurement of the label.
Several methods have been published for labelling antibodies with alkaline phosphatase 2 ) (3, 4) . Conjugation has been carried out using glutaraldehyde as a homobifunctional reagent. However, this method has the disadvantage of producing highly polymerised, heterogenous conjugates (5) . To overcome this problem we have used a heterobifunctional conjugation reagent, N-succinimidyl-3-(2-pyridyldithio)-propionate. The reaction of this compound with proteins is more easily controlled than that of glutaraldehyde, and more sensitive assays have been obtained using antibody-horse radish peroxidase 2 ) conjugates prepared with N-succinimidyl-3-(2-pyridyldithio)-propionate as compared with glutaraldehyde. The principle of the N-succinimidyl-3-(2-pyridyldithio)-propionate conjugation is to introduce 2-pyridyl-disulphide groups into proteins. One of the proteins is then thiolated by reduction of the 2-pyridyl-disulphide groups with a reducing agent. 2-Pyridyl-disulphide groups on one protein and exposed aliphatic thiol groups on the other are then allowed to react to form the conjugate.
By varying the N-succinimidyl-3-(2-pyridyldithio)-propionate/protein and the alkaline phosphatase/pro tein ratio different conjugates were obtained as shown in the first part of our study. In the second part we report the results obtained in the lEMAs of human insulin and intact proinsulin. Two monoclonal antibodies were used for each assay, one of them labelled as described with alkaline phosphatase and the other coated to a microtitre plate. An enzyme amplification step was used to obtain a sensitivity greater than that observed in the immunoradiometric assay. In this system -nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) was first converted to -nicotinamide adenine dinucleotide (NADH) by alkaline phosphatase. The NADH was then used as a cofactor in a cyclic reaction involving the enzymes diaphorase and alcohol dehydrogenase to alternately oxidize and reduce the cofactor in parallel with the reduction of a dye (8, 9) .
Materials and Methods

Materials
Human insulin standard was the first IRP (International reference preparation) coded 66/304. Intact human proinsulin was supplied by Lilly Research Laboratories, Indianapolis, Indiana 46285, USA (1). F-16 Immuno Module, flat bottom polystyrene microtitre plates were obtained from Nunc (Roskilde, Denmark). Calf intestine alkaline phosphatase was obtained from Biozyme Laboratories (Blaenavon, Gwent) as a glycerol solution containing sodium phosphate (50 mmol/1, pH 6.5), MgCl 2 (5 mmol/1) and ZnCl 2 (0.1 mmol/1), and used without further purification. The heterobifunctional reagent N-succinimidyl-3-(2-pyridyldithio)-propionate was from Pharmacia (Uppsala, Sweden). Diaphorase from pig heart was obtained from Boehringer Mannheim (Lewes, E Sussex, UK). All other chemicals and solvents were obtained from Sigma Chemical Co (Poole, Dorset, UK) or BDH (Poole, Dorset, UK).
Monoclonal antibodies 3B1, 14B and A6 were prepared as described elsewhere (1) . The IgG fraction used was prepared from the ascites fluid by precipitation with saturated ammonium sulphate (400 g/1) and affinity chromatography on DEAE Affigel Blue (10) or an Hydroxylapatite column (11) . The purity of monoclonal antibodies was assessed by electrophoresis on a 10% sodium dodecyl sulphate polyacrylamide gel (SDS PAGE). The only protein bands visualized after staining with Coomassie Brilliant Blue were those of the IgG light and heavy chains. 
c) Protein coupling
Immediately after the reduction step, the pooled fraction of modified 3B1 monoclonal antibody was added to the one of modified enzyme in a known molar ratio. The resulting solution was further concentrated to about 1.5 g/1. The reaction time was 18 -24 h at 24 °C. The coupling solution was then passed down a gel filtration column Sephadex G-200 (12 χ 1.5 cm) equilibrated in buffer A. The pooled fraction containing conjugated antibody was further purified on a FPLC Superose ™6 (Pharmacia) column using buffer C as eluent. The column was run at a flow rate of 0.3 ml/ min and 0.5 ml fractions were collected. The fractions containing conjugate were pooled and concentrated.
Protein determinations were performed using the Bio-Rad protein assay (Βίο-Rad Laboratories GmbH, W-8000 M nchen 50, Germany). The enzyme activity of the conjugate was measured using /?-nitrophenyl phosphate as substrate and the antigen binding activity of the conjugate was tested in a two-site assay of insulin (either on microtitre plates or in Eppendorf tubes) as described below. The conjugate was stored at 4 °C in buffer A or C containing bovine serum albumin (80 μιηοΐ/ΐ) and NaN 3 (3 mmol/1).
Measurement of enzyme activity
Alkaline phosphatase activity of column eluate fractions was determined using p-nitrophenyl phosphate as substrate (12) . The colour development was followed by continuous measurement at 405 nm using a V max computer-controlled microplate reader (Molecular Devices, California).
In the insulin and proinsulin assays the alkaline phosphatase activity was measured using the amplification system (8, 9) , with the change in absorbance at 490 nm measured continuously.
Measurement of antigen binding ability
This was carried out using radiolabelled human insulin (gift from Eli Lilly) and cellulose sheep anti-mouse IgG immunoadsorbent to precipitate the complexes formed between the conjugated monoclonal antibody and insulin (13) .
Immunoenzymometric assays
Microtitre plates were coated with monoconal antibody A6 and 14B at 10 or 50 mg/1 respectively in coating buffer E. Monoclonal antibody solution (200 μΐ per well) was added to the microtitre plate and incubated overnight at 4 °C. The coated strips were then washed three times with 0.5 ml/1 Tween 20 in buffer E, then blocked by incubating with 147 μιηοΐ/ΐ bovine serum albumin solution (500 μΐ per well) in buffer E for 1 to 3 h at room temperature or overnight at 4 °C. The plate was then washed (400 μΐ per well) twice with buffer F, diluted 'Λ (v/v) and containing 5 ml/1 Tween 20, and once in buffer F, diluted 'Λ (v/v). This same washing procedure was used during the assay. The coated wells were stored filled with 300 μΐ buffer E at 4 °C.
a) Insulin assay
The assay for human insulin was carried out using alkaline phosphatase-conjugated 3B1 monoclonal antibody in a twostep assay. In this procedure, sample (25 μΐ), mouse serum (3 μΐ) and 735 μηιοΙ/1 bovine serum albumin buffer F (75 μΐ) were added to 14B monoclonal antibody coated wells and incubated overnight at 4 °C. After aspiration of the solution, 100 μΐ conjugate at the appropriate optimum dilution in buffer F (0.03 μg/l for conjugate IV) was added and incubated overnight at 4 °C. The solution was aspirated and the wells washed (as described previously). The bound enzyme was detected using the amplification system. Standards were diluted in 735 μηιοΐ/l bovine serum albumin in buffer F.
b) Proinsulin assay
The proinsulin determination was carried out as described above with alkaline phosphatase-conjugated-3Bl monoclonal antibody, but with A6 monoclonal antibody coated wells and using 10 μΐ mouse serum per well.
Immunoradiometric assays
These assays were carried out as described (1) using plasma samples diluted 'Λ v/v in 735 μπιοΙ/1 bovine serum albumin in buffer F.
Results
Conjugate purification
After conjugation the mixture contained a variety of heteropolymers, free antibody and enzyme. The free antibody competing with the labelled antibody would reduce the sensitivity of the assay, whereas the free enzyme might increase the background reaction. Purification was carried out in FPLC Superose ™6 column (Pharmacia, Uppsala, Sweden) allowing the separation of the conjugates (relative molecular mass M r 250 000 and above) from the starting uncoupled enzyme and antibody ( fig. 1 ).
Variation of conjugation conditions
The conjugates listed in (1) measured value determined by quantifying the amount of pyridine-2-thione (PDP) released by reduction with dithiothreitol (2) molar excess of N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) used versus the concentration of 3B1 monoclonal antibody (3) corresponds to the enzyme activity per weight of protein in the conjugate in ΔΑ/min per mg
The effect of the number of 2-pyridyl-disulphide groups on alkaline phosphatase enzymatic activity and 3B1 monoclonal antibody binding activity is shown in figure 2 . It is apparent that introducing more than 15 2-pyridyl-disulphide groups for alkaline phosphatase and 18 for 3B1 monoclonal antibody reduces their respective activity to less than 50%.
The purification profile of the prepared conjugates on the Superose ™6 column revealed the polydisperse nature of the conjugates. Conjugate IV exhibited a larger range of relative molecular mass. These conjugates were compared in a two-site assay for insulin at a dilution presenting either similar enzymatic activity ( fig. 3a) or similar protein content ( fig. 3b) . In both experiments the polydisperse conjugate IV gave the greatest increase over background. This conjugate was used for the lEMAs of human insulin and intact proinsulin. A more precise characterisation and comparison of the different conjugates is very difficult, due to the great heterogeneity of the large molecular weight species and to the inability to determine the ratio of enzyme to antibody when either or both may be partially inactivated.
Sensitivity of IBM As
The assays detected 0.8 pmol/l or 20 attomol per well for human insulin and 0.8 pmol/l or 20 attomol per well for human intact proinsulin (mean + 3 standard deviations (SD) of the zero signal). These detection limits were lower than those of the homologous IRMAs, which were 2.3 pmol/l or 115 attomol per tube and 1.8 pmol/l or 90 attomol per tube, respectively (6).
Figures 4 and 5 show typical standard curves for IEMA of human insulin and intact proinsulin. In the former assay the cross-reactivities with intact proinsulin and 32 -33 split proinsulin were 5% at concentrations up to 200 pmol/l. In the proinsulin IEMA, the cross-reactivity of insulin was < 1 % and that of 32 -33 split proinsulin was 2.3% up to 500 pmol/l. 
Precision
The intra-run variance was tested by assaying four samples twenty times in one assay. The inter-run variance was estimated by analysis of four samples in duplicate in consecutive runs. The reproducibility of these assays was acceptable (tab. 3). Analytical recovery and dilution
The recovery of human insulin (50 -200 pmol/1) from plasma, assessed by the addition of known quantities of insulin to plasma, was 99% (range 96 -101%). In an experiment carried out with plasma of three normal fed subjects we observed a linear correlation between the degree of dilution (from neat to 1:16) and the measured concentration. The recovery of human proinsulin (6 -26 pmol/1) from plasma was 98% (range 88-112%). The serial dilution of 5 plasmas containing high concentrations of proinsulin also showed good linearity.
Discussion
The present results show that the combination of alkaline phosphatase labelling of antibodies with the amplification (cycling) system devised by Johannsson et al. (8) is capable of producing insulin and intact proinsulin assays with lower detection limits than those achieved in immunoradiometric assays using the same antibodies. We have found that 10-15 molecules of the heterobifunctional conjugation reagent N-succinimidyl-3-(2-pyridyldithio)-propionate can be linked to alkaline phosphatase or to a monoclonal antibody before either protein becomes 50% inactivated. Using a variety of conditions in which the ratios of N-succinimidyl-3-(2-pyridyldithio)-propionate to enzyme or antibody were varied, as well as the ratio of enzyme to antibody, a series of conjugates was prepared with a six fold range of the specific activity of the conjugate. It was observed that the performance of a conjugate in an assay was not simply a function of its specific activity. We have not exhaustively investigated the conditions necessary for optimising the production of conjugates for the assays, though standard curves were produced by conjugates prepared in a variety of ways, suggesting that the overall approach to conjugation is reasonably robust. Using such conjugates we have developed lEMAs for insulin and for proinsulin, the former having been in routine use for over a year. Further investigations are underway to determine the cause of the discrepant results in the proinsulin assay which may be due to interfering antibodies (14) . A simple screening test allows such samples to be identified so that they can be treated by immunoprecipitation before assay. In view of the lower detection limit, longer shelf-life of the labelled antibody and greater ease of automation we believe that such assays are superior to those achieved by direct labelling of monoclonal antibodies with 125 I.
